Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
[at noodls] – Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has received preliminary approval for $796,913 from the … moreView todays social media effects on ADXSView the latest stocks trending across Twitter. Click to view dashboardSee who Advaxis is hiring next, click here to view […]
